HC Wainwright Has Bullish Forecast for ATNM Q3 Earnings

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of Actinium Pharmaceuticals in a research report issued on Monday, August 11th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their previous forecast of ($0.35). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.26) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($1.05) EPS.

Separately, Wall Street Zen cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 12th.

Actinium Pharmaceuticals Stock Performance

Shares of NYSE:ATNM opened at $1.60 on Wednesday. The business’s fifty day moving average price is $1.59 and its two-hundred day moving average price is $1.43. The stock has a market cap of $49.91 million, a PE ratio of -1.15 and a beta of -0.53. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $2.41.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of large investors have recently bought and sold shares of ATNM. Gagnon Securities LLC acquired a new stake in Actinium Pharmaceuticals during the 1st quarter valued at $365,000. Nuveen LLC acquired a new stake in Actinium Pharmaceuticals during the 1st quarter valued at $239,000. Invesco Ltd. grew its holdings in Actinium Pharmaceuticals by 1,135.9% during the 1st quarter. Invesco Ltd. now owns 153,555 shares of the company’s stock valued at $247,000 after buying an additional 141,130 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Actinium Pharmaceuticals by 804.5% during the 4th quarter. JPMorgan Chase & Co. now owns 123,831 shares of the company’s stock valued at $156,000 after buying an additional 110,141 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in Actinium Pharmaceuticals by 413.6% during the 4th quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock valued at $155,000 after buying an additional 99,158 shares during the last quarter. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).